Genetic factors predicting response to interferon treatment for viral hepatitis C

Stärkel, Peter
April 2008
Gut;Apr2008, Vol. 57 Issue 4, p440
Academic Journal
The author comments on the study on the genetic factors predicting response of interferon (IFN) treatment for viral hepatitis C. He believes that the studies did not make it clear how the upregulation of IFN-inducible genes could determine the response rates to IFN-based therapies among patients with advanced cirrhosis or fibrosis as compared with to non-fibrotic patients regardless of the genotype that these individuals are infected with.


Related Articles

  • Locally Produced Peginterferon As An Opportunity to Treat HCV in Low and Mid-Income Countries. Mult, H. C.; Blum, H. E. // Archives of Iranian Medicine (AIM);Jul2010, Vol. 13 Issue 4, p269 

    The author reflects on the therapeutic effect of pegylated interferon alpha (PEG-IFNa) with ribavirin in treating hepatitis C virus (HCV) in low and middle income countries. He notes that antiviral strategies were developed to eliminate HCV-infection and prevent chronic hepatitis C progression...

  • Hepatitis C and direct-acting antivirals. Mangia, Alessandra // Hot Topics in Viral Hepatitis;2013, Vol. 9 Issue 27, p7 

    Treatment of chronic hepatitis C virus (HCV) has been progressively evolving during recent years. Until last year, the combination of pegylated interferon-α (PEG-IFN-α) and ribavirin (RBV), which ensures sustained virological response (SVR) rates of 45% in genotype 1-infected patients and...

  • Alpha-Interferon Treatment oc Chronic Hepatitis C: Need for Accurate Diagnosis in Selecting Patients. Black, Martin // Annals of Internal Medicine;1/1/92, Vol. 116 Issue 1, p86 

    Editorial. Comments on the issues regarding the use of alpha-interferon for the treatment of chronic hepatitis C in the U.S. as of January 1992. Views on the selection of patients for alpha-interferon therapy; Observations on research for alpha-interferon treatment; Effects of alpha-interferon.

  • Emerging Therapeutic Strategies for Hepatitis C Virus Infection. Sato, Ken; Takagi, Hitoshi; Ichikawa, Takeshi; Kakizaki, Satoru; Mori, Masatomo // Current Molecular Pharmacology;Jun2008, Vol. 1 Issue 2, p130 

    The universal prevalence of hepatitis C virus (HCV) infection, which causes chronic hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma, has become a significant health problem worldwide. Interferon-based therapies, the current standard, IFN-based therapies have limited efficacy...

  • Triple Therapy for Hepatitis C -- Boceprevir vs. Telaprevir. Tice, Alan D. // Infectious Disease Alert;Jun2011, Vol. 30 Issue 9, p100 

    The April 14 issue of the New England Journal of Medicine contains two articles on boceprevir, a new designer molecule that has demonstrated a dramatic improvement in outcomes for patients with genotype 1 hepatitis C. It is a protease inhibitor that binds reversibly to the non-structural 3 (NS3)...

  • Hepcidin Levels in Egyptian Patients with Chronic Hepatitis C and the Effect of Anti-Viral Therapy. Marzouk, Hanan A.; Zayed, Naglaa A.; Al-Ansary, Mohamed; Abdelbary, Mohamed S.; Hunter, Shereen S.; Safwat, Wael; Abdel-Moneim, Moustafa; Shaker, Olfat // World Applied Sciences Journal;2013, Vol. 22 Issue 8, p1140 

    Disruption of hepatic production of the iron regulatory hormone-hepcidin has been postulated as a possible mechanism causing iron overload in chronic hepatitis C. This study aimed at assessing the hepcidin level in CHC patients & its relation to interferon therapy. Serum iron indices and...

  • De Novo Membrano-Proliferative Nephritis Following Interferon Therapy for Chronic Hepatitis C (Case Study and Literature Review). Fabrizi, Fabrizio; Aghemo, Alessio; Moroni, Gabriella; Passerini, Patrizia; D'Ambrosio, Roberta; Martin, Paul; Messa, Piergiorgio // Digestive Diseases & Sciences;Mar2014, Vol. 59 Issue 3, p691 

    No abstract available.

  • Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. Dill, Michael T.; Makowska, Zuzanna; Trincucci, Gala; Gruber, Andreas J.; Vogt, Julia E.; Filipowicz, Magdalena; Calabrese, Diego; Krol, Ilona; Lau, Daryl T.; Terracciano, Luigi; van Nimwegen, Erik; Roth, Volker; Heim, Markus H. // Journal of Clinical Investigation;Apr2014, Vol. 124 Issue 4, p1568 

    The use of pegylated interferon-α (pegIFN-α) has replaced unmodified recombinant IFN-α for the treatment of chronic viral hepatitis. While the superior antiviral efficacy of pegIFN-α is generally attributed to improved pharmacokinetic properties, the pharmacodynamic effects of...

  • Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. Naggie, Susanna; Patel, Keyur; McHutchison, John // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2063 

    Chronic hepatitis C virus (HCV) infection is a global health problem, but the current therapy is effective in <50% of patients infected with genotype 1. With advances in cell culture systems over the past decade, the development of directly acting antivirals (DAAs) for HCV has become possible....


Read the Article


Sign out of this library

Other Topics